Hungary's single public health insurer. It pays for cancer care from screening to palliative care, buys some high-cost cancer medicines centrally, and can approve a medicine it does not normally pay for, case by case, through individual equity support.
The Nemzeti Egészségbiztosítási Alapkezelő manages Hungary's compulsory social health insurance, which the OECD and European Commission's 2025 Country Cancer Profile describes as giving access to all elements of cancer care, from screening to palliative care. In the profile's account, inpatient procedures, surgery, chemotherapy and radiotherapy are paid by diagnosis-related groups, outpatient imaging and laboratory tests by fee for service, and certain high-value treatments by itemised reimbursement from an earmarked budget, with procurement managed by the Fund. For cancer, statutory financing protocols set out the care a provider must follow, and the Fund can withdraw payment when care departs from them; new protocols for 40 diseases, several in oncology, were published with the inclusion of new cancer medicines in public financing from 1 January 2024.
For a medicine that is not reimbursed, the Fund's own page on individual support (egyedi támogatás) says it may grant equity support when the patient cannot be treated effectively with any reimbursed medicine, including for products without a Hungarian marketing authorisation that can be prescribed under a regulator's permit and for off-label use. The page, last updated in July 2024, says the Fund decides within 60 days, or out of turn for life-threatening cases and children, grants support for at most one year at first, and its decisions cannot be appealed, though they can be challenged in an administrative court within 30 days. Telex reported in June 2026 that the Batthyány-Strattmann László Foundation had decided these requests since February 2025 and that a government bill would hand its tasks back to the insurer. The Fund's notice of 1 September 2026 recalculated the support for medicines held under equity permits after VAT on prescription-only medicines fell to 0%.
Hungarian patients waited a median of just over three years for new cancer medicines to be reimbursed, and the wait was no shorter for the medicines that help most.
Part of Hungary's high recorded lung cancer mortality comes from cancers found at post-mortem examination, which the OECD links to Hungary's high autopsy rate.
Shares Hungarian National Cancer Registry (Nemzeti Rákregiszter), National Institute of Oncology, Hungary, Lung cancer (all types), Breast cancer (all types).
Shares Hungarian National Cancer Registry (Nemzeti Rákregiszter), National Institute of Oncology, Hungary, Lung cancer (all types).
Shares Hungarian National Cancer Registry (Nemzeti Rákregiszter), National Institute of Oncology, Hungary, Lung cancer (all types).
Shares Underlying reasons for post-mortem diagnosed lung cancer cases: a robust retrospective comparative study from Hungary (HULC study), National Institute of Oncology, Hungary.
Shares National Institute of Public Health of Hungary (Országos Népegészségügyi Intézet), Colorectal cancer.
Shares Hungarian National Cancer Registry (Nemzeti Rákregiszter), Lung cancer (all types).
Shares National Institute of Oncology, Hungary, Colorectal cancer.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/